Jiangsu Meishangjie Biotechnology Co., Ltd. has officially declared the successful completion of its Series A+ funding round, raising tens of millions of RMB. This round of financing was co-led by Suminhongxi Fund and Jintou Zhiyuan. The capital infusion will be strategically allocated to expedite research and development efforts within the realm of genetic engineering and synthetic biology. It will also fuel the clinical translation and market expansion of recombinant humanized collagen products, along with refining the underlying technology platform. Additionally, the company has outlined plans to set up a state-of-the-art production line for Class III medical devices in Yixing.

As an innovative frontrunner in its industry, Meishangjie Biotechnology prides itself on its cutting-edge technologies and robust platforms. Its product range spans Class II and Class III medical devices, with select offerings already progressing through the clinical trial phase. CEO Zhao Hua emphasized that this round of financing not only signifies recognition of the company's past accomplishments and future potential but also serves as a catalyst for increased investment in research and development. The company is poised to expedite product introductions and deliver superior healthcare solutions.